EUVIMEDEUVIMED entdecken
Crossref

Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024)

Bo Gu, Bing Lv, Jia Tang

Int. Journal of Clinical Pharmacology and Therapeutics · 2025

DOI: 10.5414/cp204726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Bo Gu und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Lupus Nephritis, Cyclosporine, Adverse Drug Reaction Reporting Systems, Calcineurin Inhibitors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisCyclosporineAdverse Drug Reaction Reporting SystemsCalcineurin InhibitorsImmunosuppressive AgentsHumansDatabases, FactualFemaleMaleAdultUnited StatesMiddle AgedYoung AdultPharmacovigilanceAdolescentUnited States Food and Drug Administration

Substanzen

CyclosporinevoclosporinCalcineurin InhibitorsImmunosuppressive Agents

Zitieren

APA

Gu, B., Lv, B., & Tang, J. (2025). Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024). Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204726

Vancouver

Gu B, Lv B, Tang J. Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024). Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204726

BibTeX
@article{Gu2025,
  author = {Gu, Bo and Lv, Bing and Tang, Jia},
  title = {Phase IV safety evaluation of voclosporin in lupus nephritis patients using the FAERS database for a 42-month period (2021 – 2024)},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.5414/cp204726}
}
Kostenlos starten →